Another brilliant Potpourri, with scintillating health care gems, including revising the FDA’s 510(k) process, the essential benefits package for health exchanges, the future of Medicare Advantage, the lack of labor productivity in health care, variation in elective procedure rates and the OIG’s work plan.
The Food & Drug Administration releases its strategic plan for regulatory science, identifying priority areas and implementation strategies for each. How the FDA carries out its strategy over the next few years will greatly affect both the medical products industry and overall health spending.
Our current Potpourri contains nuggets on use of robotic surgery for prostate cancer, the effect of mandated rebates in Medicare Part D on patient costs, FDA guidance on device modifications, state Medicaid EHR incentive programs, patient understanding of trial data, and use of FQHC’s by Medicaid enrollees.
The dog days of summer bring yet another scorching hot Potpourri with a smorgasbord of data, including metabias in randomized clinical trials, the practice of defensive medicine, the status of HIEs, retail pharmacy drug costs and pricing and spending on medical devices.